A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.
Comprehensive circulating tumor DNA analysis can identify therapeutically targetable driver and resistance mutations in patients with advanced non-small-cell lung cancer, research indicates.
Patients with small-cell lung cancer and brain metastases may benefit from first-line treatment with stereotactic radiosurgery, suggest findings from the FIRE-SCLC study.
The burden of severe COVID-19 tends to be high in people with lung cancer, with patient-specific factors having the greatest impact on severity, indicates a chart review from a single center.
TRK inhibitor therapy has a “unique” profile of adverse events, suggests a review of lung cancer and other oncology patients attending the Memorial Sloan Kettering Cancer Center in New York, USA.
Patients with extensive-stage small-cell lung cancer derive a progression-free survival benefit from first-line treatment with pembrolizumab plus chemotherapy, show phase 3 KEYNOTE-604 trial findings.
A phase 2 trial suggests that low-dose erlotinib has clinical activity and a favorable safety profile among older and frail non-small-cell lung cancer patients with EGFR activatingmutations.
For patients with unresectable stage III non-small-cell lung cancer, first-line pembrolizumab plus concurrent chemoradiotherapy is feasible, say the KEYNOTE-799 investigators.
Individuals with advanced non-small-cell lung cancer positive for MET exon 14 skipping mutations could benefit from treatment with the selective MET inhibitor tepotinib, suggests a phase 2 trial.
Combining osimertinib with gefitinib has promising efficacy and tolerability in treatment-naïve patients with metastatic EGFR-mutated non-small-cell lung cancer, suggest early data presented at the virtual 2020 ASCO Annual Meeting.
CheckMate 9LA findings reported at the virtual 2020 ASCO Annual Meeting support the use of nivolumab plus ipilimumab alongside first-line, histology-driven chemotherapy in advanced non-small-cell lung cancer patients without sensitizing EGFR or ALK mutations.
Patients with stage IB–IIIA non-small-cell lung cancer harboring EGFR mutations derive a significant disease-free survival benefit from adjuvant treatment with osimertinib, shows the phase 3 ADAURA trial.
Treatment with PD-1 inhibitors does not appear to worsen the severity of SARS-CoV-2 infection in patients with lung cancer, suggests a single-center analysis.
Patients with metastatic non-small-cell lung cancer may respond to adoptive cell therapy using tumor infiltrating lymphocytes, suggest results from a small phase 1 trial.
The selective EGFR–tyrosine kinase inhibitor poziotinib has clinical activity in previously treated non-small-cell lung cancer patients harboring EGFR exon 20 insertions, suggest phase 2 study data presented at the 2020 AACR Virtual Annual Meeting I.